Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cenerimod - Idorsia Pharmaceuticals

Next Previous
Drug Profile

Cenerimod - Idorsia Pharmaceuticals

Alternative Names: ACT-334441; Second selective S1P1 receptor agonist - Idorsia

Latest Information Update: 10 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Actelion Pharmaceuticals
  • Developer Idorsia Pharmaceuticals; Viatris
  • Class Antirheumatics; Oxadiazoles; Pyridines; Small molecules
  • Mechanism of Action Sphingosine 1 phosphate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Lupus nephritis; Systemic lupus erythematosus
  • Phase I Unspecified
  • Preclinical Rheumatoid arthritis
  • No development reported Autoimmune disorders

Most Recent Events

  • 18 Mar 2026 Viatris completes a phase-I Bioavailability trial (In volunteers) in Netherlands (PO, IV), (NCT07301723)
  • 12 Dec 2025 Phase-II clinical trials in Systemic lupus erythematosus (Adjunctive treatment) in China (PO) (NCT07266090)
  • 11 Dec 2025 Phase-I clinical trials in Unspecified (In volunteers) in Netherlands (IV, Infusion), (NCT07301723)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top